Glimepiride

Long-term use of glimepiride may improve survival and reduce hospitalizations in hospitalized patients with concomitant type 2 diabetes and chronic HF, researchers reported.

Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less than 7% than the sulfonylurea glimepiride or the DPP-IV inhibitor sitagliptin, according to data from the GRADE trial.

In a head-to-head study of four classes of glucose-lowering drugs, the GLP-1 receptor agonist liraglutide and insulin glargine were more effective for maintaining HbA1c below 7% than a sulfonylurea or DPP-IV inhibitor.

Adults with type 2 diabetes experienced no difference in cardiovascular autonomic neuropathy measures or B-type natriuretic peptide levels after 12 weeks of dapagliflozin therapy vs. 12 weeks of glimepiride, according to trial data.